CAMP4 Therapeutics CorporationCAMPNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank14
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Percentile
P14
Within normal range
vs 5Y Ago
-254.8x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM-1496.97%+81.0%
2024-7882.21%+45.0%
2023-14343.14%-
20220.00%-100.0%
20212.53%-56.9%
20205.88%+41.4%
20194.16%-67.9%
201812.93%+50.9%
20178.57%+21.8%
20167.04%-